Boehringer Ingelheim International GmbH and Inflammasome Therapeutics Inc. agreed to co-develop up to three candidates for retinal diseases.
BI will provide up to $160m in up-front, R&D, and milestone payments, plus tiered royalties and additional commercialization milestones. The deal combines compounds from the Big Pharma's retinal disease pipeline with Inflammasome’s intravitreal (IVT) drug delivery technologies. Inflammasome’s long-acting degradable IVT implant enables the administration of compounds to the eye as sustained-release depot formulations
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?